218 related articles for article (PubMed ID: 24450541)
1. Heat shock protein DNAJB8 is a novel target for immunotherapy of colon cancer-initiating cells.
Morita R; Nishizawa S; Torigoe T; Takahashi A; Tamura Y; Tsukahara T; Kanaseki T; Sokolovskaya A; Kochin V; Kondo T; Hashino S; Asaka M; Hara I; Hirohashi Y; Sato N
Cancer Sci; 2014 Apr; 105(4):389-95. PubMed ID: 24450541
[TBL] [Abstract][Full Text] [Related]
2. Development of an artificial antibody specific for HLA/peptide complex derived from cancer stem-like cell/cancer-initiating cell antigen DNAJB8.
Tadano H; Tsukahara T; Mizushima E; Akamatsu A; Watanabe K; Nojima I; Kubo T; Kanaseki T; Hirohashi Y; Sato N; Torigoe T
Br J Cancer; 2020 Oct; 123(9):1387-1394. PubMed ID: 32753678
[TBL] [Abstract][Full Text] [Related]
3. Cellular stress induces cancer stem-like cells through expression of DNAJB8 by activation of heat shock factor 1.
Kusumoto H; Hirohashi Y; Nishizawa S; Yamashita M; Yasuda K; Murai A; Takaya A; Mori T; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Kondo T; Sato N; Hara I; Torigoe T
Cancer Sci; 2018 Mar; 109(3):741-750. PubMed ID: 29316077
[TBL] [Abstract][Full Text] [Related]
4. Olfactory Receptor Family 7 Subfamily C Member 1 Is a Novel Marker of Colon Cancer-Initiating Cells and Is a Potent Target of Immunotherapy.
Morita R; Hirohashi Y; Torigoe T; Ito-Inoda S; Takahashi A; Mariya T; Asanuma H; Tamura Y; Tsukahara T; Kanaseki T; Kubo T; Kutomi G; Mizuguchi T; Terui T; Ishitani K; Hashino S; Kondo T; Minagawa N; Takahashi N; Taketomi A; Todo S; Asaka M; Sato N
Clin Cancer Res; 2016 Jul; 22(13):3298-309. PubMed ID: 26861454
[TBL] [Abstract][Full Text] [Related]
5. HSP DNAJB8 controls tumor-initiating ability in renal cancer stem-like cells.
Nishizawa S; Hirohashi Y; Torigoe T; Takahashi A; Tamura Y; Mori T; Kanaseki T; Kamiguchi K; Asanuma H; Morita R; Sokolovskaya A; Matsuzaki J; Yamada R; Fujii R; Kampinga HH; Kondo T; Hasegawa T; Hara I; Sato N
Cancer Res; 2012 Jun; 72(11):2844-54. PubMed ID: 22552285
[TBL] [Abstract][Full Text] [Related]
6. Immune responses to human cancer stem-like cells/cancer-initiating cells.
Hirohashi Y; Torigoe T; Tsukahara T; Kanaseki T; Kochin V; Sato N
Cancer Sci; 2016 Jan; 107(1):12-7. PubMed ID: 26440127
[TBL] [Abstract][Full Text] [Related]
7. Dnajb8, a Member of the Heat Shock Protein 40 Family Has a Role in the Tumor Initiation and Resistance to Docetaxel but Is Dispensable for Stress Response.
Yamashita M; Hirohashi Y; Torigoe T; Kusumoto H; Murai A; Imagawa T; Sato N
PLoS One; 2016; 11(1):e0146501. PubMed ID: 26751205
[TBL] [Abstract][Full Text] [Related]
8. Efficiency of G2/M-related tumor-associated antigen-targeting cancer immunotherapy depends on antigen expression in the cancer stem-like population.
Mori T; Nishizawa S; Hirohashi Y; Torigoe T; Tamura Y; Takahashi A; Kochin V; Fujii R; Kondo T; Greene MI; Hara I; Sato N
Exp Mol Pathol; 2012 Feb; 92(1):27-32. PubMed ID: 22001602
[TBL] [Abstract][Full Text] [Related]
9. Development of CAR-T cells specifically targeting cancer stem cell antigen DNAJB8 against solid tumours.
Watanabe Y; Tsukahara T; Murata K; Hamada S; Kubo T; Kanaseki T; Hirohashi Y; Emori M; Teramoto A; Nakatsugawa M; Yamashita T; Torigoe T
Br J Cancer; 2023 Mar; 128(5):886-895. PubMed ID: 36526673
[TBL] [Abstract][Full Text] [Related]
10. Identification of antigenic peptides from novel renal cancer stem-like cell antigen, DNAJB8.
Nishizawa S; Hirohashi Y; Kusumoto H; Wakamiya T; Iguchi T; Yamashita S; Iba A; Kikkawa K; Kohjimoto Y; Torigoe T; Hara I
Biochem Biophys Res Commun; 2017 Dec; 494(3-4):693-699. PubMed ID: 29107688
[TBL] [Abstract][Full Text] [Related]
11. DNAJB8 in small extracellular vesicles promotes Oxaliplatin resistance through TP53/MDR1 pathway in colon cancer.
Wang Z; Li Y; Mao R; Zhang Y; Wen J; Liu Q; Liu Y; Zhang T
Cell Death Dis; 2022 Feb; 13(2):151. PubMed ID: 35165262
[TBL] [Abstract][Full Text] [Related]
12. Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is a novel target of lung cancer stem-like cell immunotherapy.
Horibe R; Hirohashi Y; Asano T; Mariya T; Suzuki T; Takaya A; Saijo H; Shionoya Y; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Watanabe K; Atsuyama E; Toji S; Hirano H; Hasegawa T; Takahashi H; Sato N; Torigoe T
PLoS One; 2017; 12(3):e0171460. PubMed ID: 28248963
[TBL] [Abstract][Full Text] [Related]
13. Annexin A3 as a potential target for immunotherapy of liver cancer stem-like cells.
Pan QZ; Pan K; Wang QJ; Weng DS; Zhao JJ; Zheng HX; Zhang XF; Jiang SS; Lv L; Tang Y; Li YQ; He J; Liu Q; Chen CL; Zhang HX; Xia JC
Stem Cells; 2015 Feb; 33(2):354-66. PubMed ID: 25267273
[TBL] [Abstract][Full Text] [Related]
14. Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4.
Volonté A; Di Tomaso T; Spinelli M; Todaro M; Sanvito F; Albarello L; Bissolati M; Ghirardelli L; Orsenigo E; Ferrone S; Doglioni C; Stassi G; Dellabona P; Staudacher C; Parmiani G; Maccalli C
J Immunol; 2014 Jan; 192(1):523-32. PubMed ID: 24277698
[TBL] [Abstract][Full Text] [Related]
15. Autologous CTL response against cancer stem-like cells/cancer-initiating cells of bone malignant fibrous histiocytoma.
Kano M; Tsukahara T; Emori M; Murase M; Torigoe T; Kawaguchi S; Wada T; Yamashita T; Sato N
Cancer Sci; 2011 Aug; 102(8):1443-7. PubMed ID: 21518139
[TBL] [Abstract][Full Text] [Related]
16. The Antigen ASB4 on Cancer Stem Cells Serves as a Target for CTL Immunotherapy of Colorectal Cancer.
Miyamoto S; Kochin V; Kanaseki T; Hongo A; Tokita S; Kikuchi Y; Takaya A; Hirohashi Y; Tsukahara T; Terui T; Ishitani K; Hata F; Takemasa I; Miyazaki A; Hiratsuka H; Sato N; Torigoe T
Cancer Immunol Res; 2018 Mar; 6(3):358-369. PubMed ID: 29371260
[TBL] [Abstract][Full Text] [Related]
17. GRIK2 is a target for bladder cancer stem-like cell-targeting immunotherapy.
Miyata H; Hirohashi Y; Yamada S; Yanagawa J; Murai A; Hashimoto S; Tokita S; Hori K; Abe T; Kubo T; Tsukahara T; Kanaseki T; Shinohara N; Torigoe T
Cancer Immunol Immunother; 2022 Apr; 71(4):795-806. PubMed ID: 34405274
[TBL] [Abstract][Full Text] [Related]
18. Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells.
Morrison BJ; Steel JC; Morris JC
BMC Cancer; 2018 Apr; 18(1):469. PubMed ID: 29699516
[TBL] [Abstract][Full Text] [Related]
19. Susceptibility to cytotoxic T cell lysis of cancer stem cells derived from cervical and head and neck tumor cell lines.
Liao T; Kaufmann AM; Qian X; Sangvatanakul V; Chen C; Kube T; Zhang G; Albers AE
J Cancer Res Clin Oncol; 2013 Jan; 139(1):159-70. PubMed ID: 23001491
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell-based immunotherapy for colon cancer using an HLA-A*0201-restricted cytotoxic T-lymphocyte epitope from tumor-associated antigen 90K.
Hee Lee J; Park MS; Hwang JE; Cho SH; Bae WK; Shim HJ; Kim DE; Chung IJ
Cell Mol Immunol; 2013 May; 10(3):275-82. PubMed ID: 23524651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
